Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in HER2+ Vulvar Paget's Disease
NCT01427244Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Aug 2011
- Primary completion
- Sep 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in Paget's disease of the vulva, sponsored by Yale University. Planned start Aug 2011; status: withdrawn.
02
Drugs
03
Conditions
Paget's disease of the vulva
Beyond the preview
Go deeper on NCT01427244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427244.